A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies
Gianoukakis, A. G. Arnold, S. M. Kahn, S. A. Taylor, M. Garralda, E. Krebs, Matthew G Arkenau, H. T. Clark, L. Fisher, G. Subbiah, V.
Gianoukakis, A. G.
Arnold, S. M.
Kahn, S. A.
Taylor, M.
Garralda, E.
Krebs, Matthew G
Arkenau, H. T.
Clark, L.
Fisher, G.
Subbiah, V.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Gianoukakis AG, Arnold SM, Kahn SA, Taylor M, Garralda E, Krebs MG, et al. A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies. Journal of Thoracic Oncology. 2023 Apr;18(4):S87-S8. PubMed PMID: WOS:000995007600083.